WXIBF:OTC-WuXi Biologics (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.45

Change

+0.15 (+6.52)%

Market Cap

USD 8.99B

Volume

1.05K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict
Created with Highstock 5.0.6

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
WXIBF VTI
  • VTI
Relative Returns (From:    To: 2025-01-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 42.38B
UCBJY UCB SA ADR

+2.01 (+2.13%)

USD 37.09B
UCBJF UCB SA

N/A

USD 36.78B
GNMSF Genmab A/S

+5.17 (+2.45%)

USD 12.54B
WXXWY WuXi Biologics (Cayman) Inc

+0.25 (+4.30%)

USD 11.13B
IVBIY IVBIY

N/A

USD 7.80B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.33B
ZLDPF Zealand Pharma A/S

+4.29 (+4.12%)

USD 7.23B
AKESF Akeso, Inc.

+0.57 (+7.72%)

USD 7.00B
SBMFF Sino Biopharmaceutical Limited

+0.05 (+14.59%)

USD 6.93B

ETFs Containing WXIBF

DBEM Xtrackers MSCI Emerging M.. 0.00 % 0.66 %

+0.18 (+0.81%)

USD 0.07B
FLCH Franklin FTSE China ETF 0.00 % 0.19 %

+0.17 (+0.81%)

USD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.90% 69% C- 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.90% 69% C- 76% C+
Trailing 12 Months  
Capital Gain -2.00% 62% D 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.00% 62% D 50% F
Trailing 5 Years  
Capital Gain 71.60% 87% B+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 71.60% 87% B+ 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 97.35% 74% C 83% B
Dividend Return 97.35% 74% C 82% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 294.27% 29% F 19% F
Risk Adjusted Return 33.08% 84% B 69% C-
Market Capitalization 8.99B 98% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.